Juan Luis
Gómez Sirvent
Investigador en el periodo 1992-2022
Hospital Universitari de Tarragona Joan XXIII
Tarragona, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitari de Tarragona Joan XXIII (18)
2023
-
Transmitted drug resistance to antiretroviral drugs in Spain during the period 2019–2021
Journal of Medical Virology, Vol. 95, Núm. 12
2020
-
The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations
The Journal of antimicrobial chemotherapy, Vol. 75, Núm. 5, pp. 1294-1300
-
Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)
Scientific Reports, Vol. 10, Núm. 1
2019
-
Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice
The Journal of antimicrobial chemotherapy, Vol. 74, Núm. 6, pp. 1693-1700
2017
2016
-
Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV–HCV co-infected patients: final results of the Spanish BOC HIV–HCV Study
International Journal of Infectious Diseases, Vol. 53, pp. 46-51
2014
-
Incidence of Hepatitis C Virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: Increasing rates of HCV diagnosis but not of HCV seroconversions
PLoS ONE, Vol. 9, Núm. 12
-
Risk of clinically significant depression in HIV-infected patients: Effect of antiretroviral drugs
HIV Medicine, Vol. 15, Núm. 4, pp. 213-223
-
Tuberculosis in a cohort of HIV-positive patients: Epidemiology, clinical practice and treatment outcomes
International Journal of Tuberculosis and Lung Disease, Vol. 18, Núm. 6
2013
-
Incidence and risk factors of AIDS-defining cancers in a cohort of HIV-positive adults: Importance of the definition of incident cases
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 31, Núm. 5, pp. 304-312
-
Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies
AIDS, Vol. 27, Núm. 1, pp. 81-85
2012
-
Trends in mortality according to hepatitis C virus serostatus in the era of combination antiretroviral therapy
AIDS, Vol. 26, Núm. 17, pp. 2241-2246
2010
-
Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per μl in Europe and North America: A pooled cohort observational study
The Lancet, Vol. 376, Núm. 9738, pp. 340-345
2009
-
Delayed diagnosis of HIV infection in a multicenter cohort: Prevalence, risk factors, response to HAART and impact of mortality
Current HIV Research, Vol. 7, Núm. 2, pp. 224-230
-
Risk factors, CD4 long-term evolution and mortality of HIV-infected patients who persistently maintain low CD4 counts, despite virological response to HAART
Current HIV Research, Vol. 7, Núm. 6, pp. 612-619
2008
-
Incidence and risk factors for tuberculosis in HIV-positive subjects by HAART status
International Journal of Tuberculosis and Lung Disease, Vol. 12, Núm. 12, pp. 1393-1400
-
Patients' characteristics and clinical implications of suboptimal CD4 T-cell gains after 1 year of successful antiretroviral therapy
Current HIV Research, Vol. 6, Núm. 2, pp. 100-107
2000
-
Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish Earth-2 Study
Journal of Acquired Immune Deficiency Syndromes, Vol. 25, Núm. 1, pp. 26-35